Karen Small

1.1k total citations
23 papers, 781 citations indexed

About

Karen Small is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Genetics. According to data from OpenAlex, Karen Small has authored 23 papers receiving a total of 781 indexed citations (citations by other indexed papers that have themselves been cited), including 19 papers in Pulmonary and Respiratory Medicine, 16 papers in Oncology and 11 papers in Genetics. Recurrent topics in Karen Small's work include Advanced Breast Cancer Therapies (18 papers), Chronic Lymphocytic Leukemia Research (11 papers) and Cancer-related Molecular Pathways (8 papers). Karen Small is often cited by papers focused on Advanced Breast Cancer Therapies (18 papers), Chronic Lymphocytic Leukemia Research (11 papers) and Cancer-related Molecular Pathways (8 papers). Karen Small collaborates with scholars based in United States, Switzerland and Canada. Karen Small's co-authors include Rajat Bannerji, Paul Statkevich, Yali Zhu, Da Zhang, Siu‐Long Yao, Ying-Ming Jou, John Nemunaitis, Ying‐Ming Jou, Monica Mita and Haiyu Zhou and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Annals of Surgery.

In The Last Decade

Karen Small

23 papers receiving 767 citations

Peers

Countries citing papers authored by Karen Small

Since Specialization

Citations

This map shows the geographic impact of Karen Small's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Karen Small with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Karen Small more than expected).

Fields of papers citing papers by Karen Small

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Karen Small. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Karen Small. The network helps show where Karen Small may publish in the future.

Co-authorship network of co-authors of Karen Small

This figure shows the co-authorship network connecting the top 25 collaborators of Karen Small. A scholar is included among the top collaborators of Karen Small based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Karen Small. Karen Small is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Phase 1 safety, pharmacokinetic and pharmacodynamic study of the cyclin-dependent kinase inhibitor dinaciclib administered every three weeks in patients with advanced malignancies 2017 ·British Journal of Cancer ·Monica Mita, Alain C. Mita, Jennifer L. Moseley, Jennifer Poon, Karen Small, Ying-Ming Jou, Paul T. Kirschmeier, (unknown), Yali Zhu, Paul Statkevich, (unknown), John Sarantopoulos, James M. Cleary, Lucian R. Chirieac, Scott J. Rodig, Rajat Bannerji, Geoffrey I. Shapiro	48
2	Dinaciclib is a novel cyclin-dependent kinase inhibitor with significant clinical activity in relapsed and refractory chronic lymphocytic leukemia 2015 ·Leukemia ·Joseph M. Flynn, Jeffrey A. Jones, Amy J. Johnson, Leslie A. Andritsos, Kami J. Maddocks, Samantha Jaglowski, (unknown), Michael R. Grever, E. Im, Haiyu Zhou, Ying Zhu, (unknown), Karen Small, Rajat Bannerji, John C. Byrd	88
3	A Phase 3 Study to Evaluate the Efficacy and Safety of Dinaciclib Compared to Ofatumumab in Patients with Refractory Chronic Lymphocytic Leukemia 2015 ·Blood ·Paolo Ghia, Lydia Scarfò, Kumudu Pathiraja, (unknown), Karen Small, Nigel Patton	10
4	Clinical study of the novel cyclin-dependent kinase inhibitor dinaciclib in combination with rituximab in relapsed/refractory chronic lymphocytic leukemia patients 2014 ·Cancer Chemotherapy and Pharmacology ·Claire Fabre, Marco Gobbi, (unknown), Mustapha Zoubir, Marie-Paule Sablin, Karen Small, Ellie Im, (unknown), Da Zhang, Haiyu Zhou, Christophe Le Tourneau	45
5	A first-in-human, phase 1, dose-escalation study of dinaciclib, a novel cyclin-dependent kinase inhibitor, administered weekly in subjects with advanced malignancies 2013 ·Journal of Translational Medicine ·John Nemunaitis, Karen Small, Paul T. Kirschmeier, Da Zhang, Yali Zhu, Ying‐Ming Jou, Paul Statkevich, Siu‐Long Yao, Rajat Bannerji	105
6	Randomized phase 2 study of the cyclin-dependent kinase inhibitor dinaciclib (MK-7965) versus erlotinib in patients with non-small cell lung cancer 2013 ·Lung Cancer ·Joe Stephenson, John Nemunaitis, Anil A. Joy, Julie Martin, Ying‐Ming Jou, Da Zhang, Paul Statkevich, Siu‐Long Yao, Yali Zhu, Haiyu Zhou, Karen Small, Rajat Bannerji, Martin J. Edelman	81
7	Randomized Phase II Trial of the Cyclin-Dependent Kinase Inhibitor Dinaciclib (MK-7965) Versus Capecitabine in Patients With Advanced Breast Cancer 2013 ·Clinical Breast Cancer ·Monica Mita, Anil A. Joy, Alain C. Mita, Kamalesh K. Sankhala, Ying-Ming Jou, Da Zhang, Paul Statkevich, Yali Zhu, (unknown), Karen Small, Rajat Bannerji, Charles L. Shapiro	122
8	Clinical and laboratory studies of the novel cyclin-dependent kinase inhibitor dinaciclib (SCH 727965) in acute leukemias 2013 ·Cancer Chemotherapy and Pharmacology ·Ivana Gojo, Mariola Sadowska, Alison Walker, Eric J. Feldman, Swaminathan P. Iyer, Maria R. Baer, Edward A. Sausville, Rena G. Lapidus, Da Zhang, Yali Zhu, Ying-Ming Jou, Jennifer Poon, Karen Small, Rajat Bannerji	74
9	Effect of aprepitant on the pharmacokinetics of the cyclin-dependent kinase inhibitor dinaciclib in patients with advanced malignancies 2012 ·Cancer Chemotherapy and Pharmacology ·Da Zhang, Monica Mita, Geoffrey I. Shapiro, Jennifer Poon, Karen Small, Anjela Tzontcheva, Bhavna Kantesaria, Yali Zhu, Rajat Bannerji, Paul Statkevich	23
10	Phase I study of the CDK inhibitor dinaciclib (SCH 727965) in patients (pts) with relapsed/refractory CLL. 2011 ·Journal of Clinical Oncology ·Joseph M. Flynn, Justin A. Jones, Leslie A. Andritsos, Kristie A. Blum, (unknown), (unknown), Elizabeth Wiley, NA Heerema, Jennifer Poon, Karen Small, Ying-Ming Jou, (unknown), Paul Statkevich, M. R. Grever, Rajat Bannerji, John C. Byrd	10
11	A phase I study of the CDK inhibitor dinaciclib (SCH 727965) administered every 3 weeks in patients (pts) with advanced malignancies: Final results. 2011 ·Journal of Clinical Oncology ·Monica Mita, Akira Mita, Jennifer L. Moseley, Jennifer Poon, Karen Small, Ying-Ming Jou, Paul T. Kirschmeier, (unknown), Paul Statkevich, Kamalesh K. Sankhala, John Sarantopoulos, (unknown), Lucian R. Chirieac, Scott J. Rodig, Rajat Bannerji, Geoffrey I. Shapiro	12
12	Early Evidence of Anti-Lymphoma Activity of the Cyclin Dependent Kinase Inhibitor Dinaciclib (SCH 727965) In Heavily Pre-Treated Low Grade Lymphoma and Diffuse Large Cell Lymphoma Patients 2010 ·Blood ·Robert A. Baiocchi, Joseph M. Flynn, Jeffrey A. Jones, Kristie A. Blum, Craig C. Hofmeister, Jennifer Poon, Karen Small, Paul Statkevich, Michael R. Grever, Rajat Bannerji, John C. Byrd	9
13	Phase II Study of the Cyclin-Dependent Kinase (CDK) Inhibitor Dinaciclib (SCH 727965) In Patients with Advanced Acute Leukemias 2010 ·Blood ·Ivana Gojo, Alison Walker, (unknown), Eric J. Feldman, Swaminathan P. Iyer, Maria R. Baer, Jennifer Poon, Karen Small, Da Zhang, Mariola Sadowska, Rajat Bannerji	12
14	A phase I dose-escalation study of the safety, pharmacokinetics (PK), and pharmacodynamics (PD) of SCH 727965, a novel cyclin-dependent kinase inhibitor, administered weekly in subjects with advanced malignancies 2009 ·Journal of Clinical Oncology ·John Nemunaitis, (unknown), Mitchell Rosenberg, Divis Khaira, Karen Small, Paul T. Kirschmeier, Paul Statkevich, Malaz Abutarif, Siu‐Long Yao, Rajat Bannerji	12
15	The Cyclin Dependent Kinase Inhibitor SCH 727965 Demonstrates Promising Pre-Clinical and Early Clinical Activity in Chronic Lymphocytic Leukemia. 2009 ·Blood ·Joseph M. Flynn, Amy J. Johnson, Leslie A. Andritsos, Kristie A. Blum, Jeffrey A. Jones, Elizabeth Wiley, Weihong Hu, Joshua Hessler, Lisa L. Smith, David Lucas, Karen Small, Paul Statkevich, Michael R. Grever, Rajat Bannerji, John C. Byrd	6
16	A phase I dose-escalation study of the safety, pharmacokinetics (PK) and pharmacodynamics (PD) of the novel cyclin-dependent kinase inhibitor SCH 727965 administered every 3 weeks in subjects with advanced malignancies 2008 ·Journal of Clinical Oncology ·Geoffrey I. Shapiro, Rajat Bannerji, Karen Small, Sherry R. Black, Paul Statkevich, Malaz Abutarif, Jennifer L. Moseley, Siu‐Long Yao, Chris H. Takimoto, Monica Mita	17
17	Improved Outcome of Surgical Flaps Treated with Topical Dimethylsulfoxide 1996 ·Annals of Surgery ·(unknown), Rodney F. Pommier, Shauna T. Williams, (unknown), Karen Small, William S. Fletcher	29
18	Results of cisplatin hyperthermic isolation perfusion for stage IIIA and IIIAB extremity melanoma. 1994 ·PubMed ·William S. Fletcher, Rodney F. Pommier, Karen Small	14
19	Pharmacokinetics and results of dose escalation inCis-platin hyperthermic isolation limb perfusion 1994 ·Annals of Surgical Oncology ·William S. Fletcher, Rodney F. Pommier, Eugene A. Woltering, (unknown), (unknown), Karen Small	14
20	Phase I-II trial of hyperthermic isolated limb perfusion with cisplatin in the treatment of high risk malignant melanoma of the extremities 1991 ·Melanoma Research ·(unknown), Carlheinz R. Mueller, Eugene A. Woltering, Karen Small, William S. Fletcher	13

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact